Reloading Prasugrel or Clopidogrel on High Platelet Reactivity Before Percutaneous Coronary Intervention

• Status: Completed
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

High platelet reactivity unit (PRU) after loading dose clopidogrel in patients undergoing percutaneous coronary intervention (PCI) is related to high risk of short and long term recurrent ischemic events including stent thrombosis.

The investigators hypothesize that additional loading of prasugrel in patients with high PRU after clopidogrel loading would be superior to additional loading of clopidogrel in reducing platelet reactivity and thereby result in lower risk of short term recurrent ischemic events.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dong-A University
• Treatments: Clopidogrel; Prasugrel Hydrochloride; Ticlopidine

Criteria

Inclusion Criteria:

• Acute coronary syndrome

• Patients planned to undergo percutaneous transluminal coronary angioplasty

• Patients who agreed to the experimental plan which was permitted by IRB

Exclusion Criteria:

• Low body weight (<50kg)

• Urgent PCI for ACS

• Use of glycoprotein IIb/IIIa inhibitor in recent 24hrs or planned to

• History of transient ischemic attack

• History of upper gastrointestinal bleeding in recent 6 months

• Renal dysfunction defined as serum creatinine > 2.5 mg/dl

• Severe hepatic dysfunction defined as serum transaminase > 3 times normal limit

• Bleeding tendency

• Anticoagulation treatment including warfarin

• Thrombocytopenia defined by platelet < 100,000/ml

• Anemia defined by hemoglobin < 10 g/dl

• Contraindication for study drugs